SARA KLEIN: Open Payments
NPI 1689120776 · O FALLON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,023 in 57 payments from 17 companies in 2025. Trend: 2023 $831 · 2024 $780 · 2025 $1,023
Food & beverage: $1,023
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $317 |
| Lilly USA, LLC | 7 | $166 |
| Novo Nordisk Inc | 5 | $82 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $62 |
| Abbott Laboratories | 3 | $61 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 3 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Tris Pharma Inc | 2 | $36 |
| PFIZER INC. | 2 | $31 |
Products named: VRAYLAR, UBRELVY, MOUNJARO, JARDIANCE, Ozempic, FREESTYLE LIBRE 3, QULIPTA, SHINGRIX.
Industry payments across MO — which companies pay providers there.
